Therapeutic strategies in Friedreich's ataxia

Journal of Neural Transmission, Supplement

Volumn , Issue 68, 2004, Pages 135-145

  Schols L ^a   Meyer, Ch ^b   Schmid, G ^b   Wilhelms, I ^b   Przuntek, H ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRIDYLCARBOXALDEHYDE ISONICOTINOYLHYDRAZONE; ACONITATE HYDRATASE; ALPHA TOCOPHEROL; ANTIOXIDANT; BIOLOGICAL MARKER; CARNITINE; CHELATING AGENT; DEFEROXAMINE; FRATAXIN; IDEBENONE; IRON; IRON SULFUR PROTEIN; UBIDECARENONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; FRIEDREICH ATAXIA; GENE TRANSFER; GENETIC ANALYSIS; HUMAN; IRON OVERLOAD; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOGENESIS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; STEM CELL TRANSPLANTATION;

EID: 4544358358     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0579-5_16     Document Type: Review

References (37)

1. Artuch R, Aracil A, Mas A, Colome C, Rissech M, Monros E, Pineda M (2002) Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33: 190-193
2. Babcock M, de Silva D, Oaks R, Davis-Kaplan S, Jiralerspong S, Montermini L, Pandolfo M, Kaplan J (1997) Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science 276: 1709-1712
3. Bidichandani SI, Ashizawa T, Patel PI (1998) The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 62: 111-121
4. Buyse G, Mertens L, Di Salvo G, Matthijs I, Weidemann F, Eyskens B, Goossens W, Goemans N, Sutherland GR, Van Hove JL (2003) Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60: 1679-1681
5. Campuzano V, Montermini L, Moltò MD, et al. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271: 1423-1427
6. Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, Trottier Y, Kish SJ, Faucheux B, Trouillas P, Authier FJ, Durr A, Mandel JL, Vescovi A, Pandolfo M, Koenig M (1997) Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 6: 1771-1780
7. Cossee M, Durr A, Schmitt M, Dahl N, Trouillas P, Allinson P, Kostrzewa M, Nivelon-Chevallier A, Gustavson KH, Kohlschutter A, Muller U, Mandel JL, Brice A, Koenig M, Cavalcanti F, Tammaro A, De Michele G, Filla A, Cocozza S, Labuda M, Montermini L, Poirier J, Pandolfo M (1999) Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 45: 200-206
8. Cossee M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, LeMeur M, Fischbeck K, Dolle P, Koenig M (2000) Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 9: 1219-1226
9. Delatycki MB, Camakaris J, Brooks H, Evans-Whipp T, Thorburn DR, Williamson R, Forrest SM (1999) Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann Neurol 45: 673-675
10. Devereux RB, Reichek N (1977) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55: 613-618
11. Dürr A (2002) Friedreich's ataxia: treatment within reach. Lancet Neurol 1: 370-374
12. Dürr A, Cossée M, Agid Y, et al. (1996) Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 335: 1169-1175
13. n tract in the Friedreich Ataxia (STM7) gene. Hum Genet 99: 834-836
14. Foury F, Cazzalini O (1997) Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett 411: 373-377
15. Friedreich N (1863) Über degenerative Atrophie der spinalen Hinterstränge. Virchows Arch Pathol Anat Physiol 26: 391-419
16. Harding AE (1981) Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104: 589-620
17. Hausse AO, Aggoun Y, Bonnet D, et al. (2002) Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87: 346-349
18. Infanate JP, Huszagh VA (2000) Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett 468: 1-5
19. Lamarche JB, Cote M, Lemieux B (1980) The cardiomyopathy of Friedreich's ataxia - morphological observations in 3 cases. Can J Neurol Sci 7: 389-396
20. Lodi R, Cooper JM, Bradley JL, et al. (1999) Deficit of in vivo mitochondrial ATP production in Patients with Friedreich's ataxia. Proc Natl Acad Sci USA 96: 11492-11495
21. Lodi R, Hart PE, Rajagopalan B, et al. (2001) Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol 49: 590-596
22. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S (2003) Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60: 1676-1679
23. Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, Hindelang C, Matyas R, Rustin P, Koenig M (2001) Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 27: 181-186
24. Richardson DR (2003) Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin Invest Drugs 12: 235-245
25. Ristow M, Pfister MF, Yee AJ, Schubert M, Michael L, Zhang CY, Ueki K, Michael MD 2nd, Lowell BB, Kahn CR (2000) Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci USA 97: 12239-12243
26. Rötig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P (1997) Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet 17: 215-217
27. Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A (1999) Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354: 477-479
28. Rustin P, Rotig A, Munnich A, Sidi D (2002) Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic Res 36: 467-469
29. Schöls L, Amoiridis G, Przuntek H, et al. (1997) Friedreich's ataxia: revision of the phenotype according to molecular genetics. Brain 120: 2131-2140
30. Schöls L, Vorgerd M, Schillings M, Skipka G, Zange J (2001) Idebenone in patients with Friedreich ataxia. Neurosci Lett 306: 169-172
31. Schöls L, Vorgerd M, Abele M, Schillings M, Skipka G, Müller K, Klockgether T, Przuntek H, Zange J (2002) A placebo-controlled crossover trial of carnitine and creatine in Friedreich's ataxia. J Neurol 249 [Suppl I]: 56
32. Schulz J, Dehmer T, Schöls L, Mende H, Hardt C, Vorgerd M, Bürk K, Dichgans J, Beal MF, Bogdanov MB (2000) Oxidative stress in Friedreich ataxia. Neurology 55: 1719-1721
33. Sorbi S, Forleo P, Fani C, Piacentini S (2000) Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxias. Clin Neuropharmacol 23: 114-118
34. Tan G, Napoli E, Taroni F, Cortopassi G (2003) Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet 12: 1699-1711
35. Vorgerd M, Schöls L, Hardt C, Ristow M, Epplen JT, Zange J (2000) Mitochondrial impairment of human muscle in Friedreich ataxia in vivo. Neuromuscular Disord 10: 430-435
36. Waldvogel D, van Gelderen P, Hallett M (1999) Increased iron in the dentate nucleus of patients with Friedrich's ataxia. Ann Neurol 46: 23-125
37. Wilson RB, Roof DM (1997) Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat Genet 16: 352-357